Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Partial vs Radical Nephrectomy Impact on Survival

Eur Urol Focus; ePub 2018 Feb 2; Marchioni, et al

Partial nephrectomy (PN) may help prevent renal insufficiency, hypertension, and other unfavorable health outcomes in older people with nonmetastatic T1a renal cell carcinoma (RCC), according to a study involving >4,500 individuals. Participants were ≥75 years of age with surgically-treated nonmetastatic T1a RCC. Investigators looked at the impact partial vs radical nephrectomy had on other-cause, cancer-specific, and 30-day mortality. Among the results:

  • 42% of patients had partial nephrectomy.
  • Those undergoing partial nephrectomy were 33% less likely than those who had radical nephrectomy to experience other-cause mortality.
  • The favorable outcome was seen across all ages evaluated.
  • Those in the partial nephrectomy group were 36% less likely to experience cancer-specific mortality.
  • 30-day mortality rates did not differ.


Marchioni M, Preisser F, Bandini M, et al. Comparison of partial versus radical nephrectomy effect on other-cause mortality, cancer-specific mortality, and 30-day mortality in patients older than 75 years. [Published online ahead of print February 2, 2018]. Eur Urol Focus. doi:10.1016/j.euf.2018.01.007

This Week's Must Reads

Case studies shed light on treatment for rare form of MCL , Mori S et al. Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):e93-7.

Histopathological clues for differentiating follicular lymphomas, Servitje O et al. J Cutan Pathol. 2019;46:182-9.

Single agent daratumumab is not an option in B-cell lymphomas, Salles G et al. Clin Lymphoma Myeloma Leuk. 2019 Jan 2. doi: 10.1016/j.clml.2018.12.013.

Ibrutinib combo advances in CNS lymphoma, Grommes C et al. Blood. 2019;133(5):436-45.

Best frontline options for advanced follicular lymphoma, Shah NN et al. Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):95-102.

Must Reads in Renal Cell Carcinoma

Strong link found between RCC and melanoma, Kim KB et al. Cancer Epidemiol. 2018 Oct 19;57:80-4

Apo B/A1 predicts survival in metastatic renal cell carcinoma, Zhang F et al. Urol Oncol. 2018 Nov 30. doi: 10.1016/j.urolonc.2018.11.010

RCC patients with brain-only metastases may benefit from cytoreductive nephrectomy, Daugherty M et al. Urol Oncol. 2018 Dec 5.doi: 10.1016/j.urolonc.2018.10.021

Lower concentration of pazopanib linked with less toxicity, Noda S et al. Clin Genitourin Cancer. 2018 Dec 7. doi: 10.1016/j.clgc.2018.12.001

One-fourth of placebo arm experience adverse events in RCC trials, Chacón M et al. JAMA Network Open. 2018 Dec 7. doi: 10.1001/jamanetworkopen.2018.5617